natgillin/translations-raw huggingface dataset:
In a pool of ten placebo-controlled and active-controlled trials of patients treated with alirocumab 75 mg and/or 150 mg Q2W as well as in a separate clinical study of patients treated with alirocumab 75 mg Q2W or 300 mg every 4 weeks (including some patients with dose adjustment to 150 mg Q2W), the incidence of detecting ADA and NAb was similar to the results from the ODYSSEY OUTCOMES trial described above.
V kumulativni obravnavi desetih s placebom oziroma aktivno kontroliranih preskušanj pri bolnikih, zdravljenih s 75 mg in/ali 150 mg alirokumaba na 2 tedna, ter v ločeni klinični študiji bolnikov, zdravljenih s 75 mg alirokumaba na 2 tedna ali 300 mg alirokumaba na 4 tedne (vključno z nekaterimi bolniki, ki so jim odmerek prilagodili na 150 mg na 2 tedne) je bila pojavnost zaznanih ADA in NAb podobna zgoraj opisanim rezultatom preskušanja ODYSSEY OUTCOMES.
The pharmacokinetics of alirocumab after single subcutaneous administration of 75 mg into the abdomen, upper arm or thigh were similar.
Farmakokinetika alirokumaba je bila po enkratnem subkutanem injiciranju 75 mg v trebuh, nadlaket ali stegno podobna.
Week24 LDL-C (ITT)
24. teden h‐LDL (ZNZ)
If you are not sure when to inject Praluent, call your doctor, pharmacist or nurse.
Če ste negotovi, kdaj injicirati zdravilo Praluent, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Upper respiratory tract signs and symptoms*
Bolezni dihal, prsnega koša in mediastinalnega prostora znaki in simptomi na zgornjih dihalih*
The pen will not work if the yellow safety cover is not depressed fully.
Če rumeni varnostni ščitnik ni povsem pritisnjen, peresnik ne bo deloval.
Unstable angina requiring hospitalization c
b Nestabilna angina pektoris, ki je zahtevala sprejem v bolnišnico.
 Push and immediately release the grey button with your thumb.
 S palcem pritisnite sivi gumb in ga takoj spustite.
Alirocumab exposure (AUC0-14d) at steady state at both the 75 and 150 mg Q2W dosing regimen was decreased by 29% and 36% in patients weighing more than 100 kg as compared to patients weighing between 50 kg and 100 kg.
Izpostavljenost alirokumabu (AUC0-14d) se je v stanju dinamičnega ravnovesja z obema odmernima shemama (75 in 150 mg na 2 tedna) zmanjšala za 29 % in 36 % pri bolnikih, ki so tehtali več kot 100 kg, v primerjavi s tistimi, ki so tehtali od 50 do 100 kg.
1, 2, or 6 pre-filled syringes.
1, 2 ali 6 napolnjenih injekcijskih brizg.
Non-HDL-C
TG h‐HDL
Number of patients Mean Baseline LDL-C in mg/dL (mmol/L) Week 12
Število bolnikov Povprečni izhodiščni h‐LDL v mg/dl (mmol/l) 12. teden h‐LDL (ZNZ)
Patients received either alirocumab 75 mg Q2W or ezetimibe 10 mg once daily, or atorvastatin 20 mg once daily (as a re-challenge arm).
Bolniki so prejemali ali alirokumab v odmerku 75 mg na 2 tedna ali ezetimib 10 mg enkrat na dan ali atorvastatin 20 mg enkrat na dan (kot skupina s ponovno provokacijo).
Pharmacokinetic/pharmacodynamic relationship(s)
Razmerje farmakokinetika/farmakodinamika
It is available in pack size of 1, 2 or 6 pre-filled syringes.
Na voljo je v pakiranjih z 1, 2 ali 6 napolnjenimi injekcijskimi peresniki.
In a phase 1 study, after administration of a single 75 mg subcutaneous dose, alirocumab pharmacokinetic profiles in subjects with mild and moderate hepatic impairment were similar as compared to subjects with normal hepatic function.
V študiji 1. faze je bil farmakokinetični profil alirokumaba po uporabi enkratnega subkutanega odmerka 75 mg pri preiskovancih z blago in zmerno okvaro jeter podoben kot pri preiskovancih z normalnim delovanjem jeter.
A multicenter, double-blind, placebo-controlled, 48 week study included 540 patients on a maximally tolerated dose of a statin, with or without other lipid-modifying therapy (308 in the alirocumab 300 mg Q4W group, 76 in the alirocumab 75 mg Q2W group, and 156 in the placebo group), and 252 patients not treated with a statin (144 in the alirocumab 300 mg Q4W group, 37 in the alirocumab 75 mg Q2W group, and 71 in the placebo group).
Multicentrična, dvojno slepa s placebom kontrolirana 48-tedenska študija je zajela 540 bolnikov, ki so prejemali največji tolerirani odmerek statina, z drugimi lipolitičnimi zdravili ali brez njih (309 v skupini s 300 mg alirokumaba na 4 tedne, 76 v skupini s 75 mg alirokumaba na 2 tedna in 156 v skupini s placebom), ter 252 bolnikov, ki niso prejemali statina (144 v skupini s 300 mg alirokumaba na 4 tedne, 37 v skupini s 75 mg alirokumaba na 2 tedna in 71 v skupini s placebom).
 Push and immediately release the green button with your thumb.
 S palcem pritisnite zeleni gumb in ga takoj spustite.
The syringe components are assembled into a single-use pre-filled pen with a blue cap and a dark grey activation button.
Elementi brizge so sestavljeni v napolnjen injekcijski peresnik za enkratno uporabo z modrim pokrovčkom in temno sivim gumbom za aktiviranje.
Difference versus ezetimibe was statistically significant at week 24 for all lipids/ lipoproteins except for TG, and Apo A-1.
Razlika v primerjavi z ezetimibom je bila 24. teden statistično značilna za vse lipide/lipoproteine razen za TG in Apo A-1.
No dose adjustment is needed for patients with mild or moderate hepatic impairment.
Bolnikom z blago ali zmerno okvaro jeter odmerka ni treba prilagoditi.
Difference versus ezetimibe was statistically significant at week 24 for LDL-C, Total-C, Non-HDL-C, Apo B, and Lp(a).
Razlika v primerjavi z ezetimibom je bila 24. teden statistično značilna za h-LDL, celokupni holesterol, ne-HDL, Apo B in Lp(a).
A multicenter, double-blind, ezetimibe-controlled 2 year study included 707 patients categorised as very high CV risk and not at their pre-defined target LDL-C on a maximally tolerated dose of statin.
Ta multicentrična dvojno slepa, z ezetimibom kontrolirana 2-letna študija je zajela 707 bolnikov, ki so imeli zelo visoko KV tveganje in z največjim toleriranim odmerkom statina niso dosegli vnaprej opredeljenega ciljnega h-LDL.
Body weight No dose adjustment is needed in patients based on weight.
Telesna masa Odmerka ni treba prilagoditi glede na bolnikovo telesno maso.
To give the 300 mg dose, give two 150 mg injections in a row at two different injection sites.
Za dajanje odmerka 300 mg je treba dati dve 150-mg injekciji zapored na dve različni mesti.
It is available in pack size of 1, 2 or 6 pre-filled pens.
Na voljo je v pakiranjih z 1, 2 ali 6 napolnjenimi injekcijskimi brizgami.
Placebo Alirocumab
Alirokumab
Based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab as monotherapy at subcutaneous doses of either 75 mg Q2W or 150 mg Q2W.
Na podlagi populacijske farmakokinetične analize je mediani navidezni razpolovni čas alirokumaba v stanju dinamičnega ravnovesja pri bolnikih, ki so alirokumab dobivali kot monoterapijo v subkutanih odmerkih 75 mg na 2 tedna ali 150 mg na 2 tedna, od 17 do 20 dni.
Mean Percent Change from Baseline in Ezetimibe-Controlled Studies On Background Statin
Povprečna odstotna sprememba v primerjavi z izhodiščem v študijah, kontroliranih z ezetimibom
General allergic reactions, including pruritus, as well as rare and sometimes serious allergic reactions such as hypersensitivity, nummular eczema, urticaria, and hypersensitivity vasculitis have been reported in clinical studies (see section 4.8).
V kliničnih študijah so bile opisane splošne alergijske reakcije, med njimi srbenje, pa tudi redke in včasih resne alergijske reakcije, kot so preobčutljivost, numularni ekcem, urtikarija in preobčutljivostni vaskulitis (glejte poglavje 4.8).
A multicenter, double-blind, ezetimibe-controlled, 24 week study included 103 patients with a moderate CV risk, not taking statins or other lipid-modifying therapies, and a baseline LDL-C between 100 mg/dL (2.59 mmol/L) to 190 mg/dL (4.91 mmol/L).
Ta multicentrična dvojno slepa, z ezetimibom kontrolirana 24-tedenska študija je zajela 103 bolnike z zmernim KV tveganjem, ki niso jemali statinov ali drugih zdravil za prilagoditev lipidov in so imeli izhodiščni h-LDL med 100 mg/dl (2,59 mmol/l) in 190 mg/dl (4,91 mmol/l).
LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.
LDLR je primarni receptor, ki odstranjuje LDL v obtoku, zato znižanje ravni LDLR zaradi PCSK9 zviša koncentracijo h-LDL v krvi.
Store unused syringes in the refrigerator at 2°C to 8°C.
Neuporabljene brizge shranjujte v hladilniku pri temperaturi od 2 do 8 °C.
The mean LDL-C value at baseline was 92.4 mg/dL (2.39 mmol/L).
Povprečni izhodiščni hLDL je bil 92,4 mg/dl (2,39 mmol/l).
Population pharmacokinetic analyses showed that alirocumab exposure (AUC0-14d) at steady state at both the 75 and 150 mg Q2W dosing regimen was increased by 22%-35%, and 49%-50% in patients with mild and moderate renal impairment, respectively, compared to patients with normal renal function.
Populacijske farmakokinetične analize so pokazale, da se je izpostavljenost alirokumabu (AUC0-14d) v stanju dinamičnega ravnovesja v primerjavi z bolniki z normalnim delovanjem ledvic z obema odmernima shemama (75 mg in 150 mg na dva tedna) pri bolnikih z blago okvaro ledvic povečala za 22 do 35 %, pri bolnikih z zmerno okvaro ledvic pa za 49 do 50 %.
In addition, rare and sometimes serious allergic reactions such as hypersensitivity, nummular eczema, urticaria, and hypersensitivity vasculitis have been reported in controlled clinical studies (See section 4.4).
Poleg tega so bile v kontroliranih kliničnih študijah opisane redke in včasih resne alergijske reakcije, na primer preobčutljivost, numularni ekcem, urtikarija in preobčutljivostni vaskulitis (glejte poglavje 4.4).
A third multicenter, double-blind, placebo-controlled 18-month study included 106 heFH patients on a maximally tolerated dose of statin, with or without other lipid-modifying therapies, and a baseline LDL-C ≥160 mg/dL (≥4.14 mmol/L).
Tretja multicentrična, dvojno slepa s placebom kontrolirana 18-mesečna študija je zajela 106 bolnikov s heFH, ki so jemali največji tolerirani odmerek statina, z drugimi zdravili za prilagoditev lipidov ali brez njih, in so imeli izhodiščni h-LDL ≥ 160 mg/dl (≥ 4,14 mmol/l).
Adverse reactions are presented by system organ class.
Neželeni učinki so prikazani po organskih sistemih.
Dose adjustment in the alirocumab groups to 150 mg Q2W occurred at week 12 in patients with LDL-C ≥70 mg/dL or ≥100 mg/dL, depending on their level of CV risk, or in patients who did not have at least a 30% reduction of LDL-C from baseline.
V skupinah z alirokumabom so odmerek alirokumaba 12. teden prilagodili na 150 mg na 2 tedna pri bolnikih, ki so imeli h-LDL ≥ 70 mg/dl oz. ≥ 100 mg/dl, odvisno od njihovega srčnožilnega tveganja, in pri bolnikih, ki od izhodišča niso dosegli vsaj 30-odstotnega znižanja h-LDL.
In patients treated beyond 12 weeks, the dose was adjusted to 150 mg Q2W in 56 (19.3%) of 290 patients in the alirocumab 300 mg Q4W arm.
Med bolniki, zdravljenimi več kot 12 tednov, so odmerek prilagodili na 150 mg na 2 tedna pri 56 (19,3 %) od 290 bolnikov v skupini s 300 mg alirokumaba na 4 tedne.
LDL-C (on treatment)
a h‐LDL (med zdravljenjem)
In pre-specified analyses of pooled phase 3 studies, treatment-emergent CV events confirmed by adjudication, consisting of coronary heart disease (CHD) death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalisation, congestive heart failure hospitalisation, and revascularisation, were reported in 110 (3.5%) patients in the alirocumab group and 53 (3.0%) patients in the control group (placebo or active control) with HR=1.08 (95% CI, 0.78 to 1.50).
V vnaprej opredeljenih kumulativnih analizah študij 3. faze so se med zdravljenjem nastali KV dogodki, potrjeni s presojo (ki so obsegali smrt zaradi koronarne bolezni srca, miokardni infarkt, ishemično možgansko kap, nestabilno angino pektoris, ki je zahtevala sprejem v bolnišnico, sprejem v bolnišnico zaradi kongestivnega srčnega popuščanja in revaskularizacijo), pojavili pri 110 (3,5 %) bolnikih v skupini z alirokumabom in pri 53 (3,0 %) bolnikih v kontrolni skupini (placebo ali kontrolna učinkovina); razmerje ogroženosti (ROg) = 1,08 (95 % IZ 0,78 do 1,50).
Major adverse cardiovascular events (“MACEplus”, i.e.: CHD death, myocardial infarction, ischemic stroke, and unstable angina requiring hospitalisation) confirmed by adjudication were reported in 52 of 3182 (1.6%) patients in the alirocumab group and 33 of 1792 (1.8%) patients in the control group (placebo or active control); HR=0.81 (95% CI, 0.52 to 1.25).
S presojo potrjeni hujši neželeni kardiovaskularni učinki (“MACE-plus”: smrt zaradi koronarne bolezni, miokardni infarkt, ishemična možganska kap ali nestabilna angina pektoris, ki zahteva sprejem v bolnišnico) so se pojavili pri 52 od 3182 (1,6 %) bolnikov v skupini z alirokumabom in pri 33 od 1792 (1,8 %) bolnikov v kontrolni skupini (placebo ali kontrolna učinkovina); ROg = 0,81 (95 % IZ, 0,52 do 1,25).
The efficacy of alirocumab was investigated in ten phase 3 trials (five placebo-controlled and five ezetimibe-controlled studies), involving 5296 randomised patients with hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, with 3188 patients randomised to alirocumab.
Povzetek programa kliničnih preskušanj 3. faze - odmerna shema 75 mg in/ali 150 mg na 2 tedna Učinkovitost alirokumaba so raziskali v desetih preskušanjih 3. faze (petih s placebom kontroliranih in petih z ezetimibom kontroliranih študijah), ki so zajele 5296 randomiziranih bolnikov s hiperholesterolemijo (heterozigotno familiarno ali nefamiliarno) ali mešano dislipidemijo; 3188 bolnikov je bilo randomiziranih na alirokumab.
In patients treated beyond 12 weeks, the dose was adjusted to 150 mg Q2W in 19 (14.7%) of 129 patients in the alirocumab 300 mg Q4W arm.
Med bolniki, zdravljenimi več kot 12 tednov, so odmerek prilagodili na 150 mg na 2 tedna pri 19 (14,7 %) od 129 bolnikov v skupini s 300 mg alirokumaba na 4 tedne.
A concentration-dependent reduction in free PCSK9 and LDL-C is observed until target saturation is achieved.
Dokler ni dosežena zasičenost ciljnega mesta, je opazno od koncentracije odvisno znižanje prostega PCSK9 in h-LDL.
Dose up-titration of alirocumab to 150 mg Q2W occurred at week 12 in patients with LDL-C ≥70 mg/dL (≥1.81 mmol/L).
Odmerek alirokumaba so 12. teden povečali na 150 mg na 2 tedna pri bolnikih, ki so imeli h-LDL ≥ 70 mg/dl (≥ 1,81 mmol/l).
Praluent is a clear, colourless to pale yellow solution for injection that comes in a pre-filled pen.
Zdravilo Praluent je bistra, brezbarvna do bledo rumena raztopina za injiciranje v napolnjenem injekcijskem peresniku.
To administer the 300 mg dose, give two 150 mg injections consecutively at two different injection sites.
Pri uporabi odmerka 300 mg je treba dati dve 150-mg injekciji zaporedoma na dve različni mesti.
MACE-plus defined as a composite of: coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, or unstable angina (UA) requiring hospitalization b
0,0261f a MACE-plus, opredeljen kot sestavljeni izid smrti zaradi koronarne bolezni, miokardnega infarkta (MI) brez smrtnega izida, možganske kapi s smrtnim izidom ali brez njega, ali nestabilne angine pektoris, ki zahteva sprejem v bolnišnico.
• Use a 90º angle if you can pinch 5 cm of skin.
• Če lahko v gubo stisnete 5 cm kože, zabodite pod kotom 90 stopinj.
Ezetimibe-controlled phase 3 trials in patients with primary hypercholesterolaemia (without a background statin)
Z ezetimibom kontrolirana preskušanja 3. faze pri bolnikih s primarno hiperholesterolemijo (brez osnovnega statina)
Placebo-controlled phase 3 studies (on background statin) in patients with heterozygous familial hypercholesterolaemia (heFH)
S placebom kontrolirane študije 3. faze (z osnovnim statinom) pri bolnikih s heterozigotno familiarno hiperholesterolemijo (heFH)
Throw away pen and cap
 Brizgo in pokrovček zavrzite
• Do not put the grey needle cap back on.
• Sivega pokrovčka igle ne nameščajte nazaj.
• cotton ball or gauze
• kosem vate ali gazo
Eight studies were performed with a dose of 75 mg Q2W, and criteria-based up-titration to 150 mg Q2W at week 12 in patients who did not achieve their pre-defined target LDL-C based on their level of CV risk at week 8.
Osem študij je bilo izvedenih z odmerkom 75 mg na 2 tedna; bolnikom, ki 8. teden niso dosegli ciljnega h-LDL glede na svojo raven KV tveganja, so na podlagi meril odmerek 12. teden povečali na 150 mg na 2 tedna.
The difference versus placebo was statistically significant at week 24 for all lipids/ lipoproteins except TG and Apo A-1.
Razlika v primerjavi s placebom je bila 24. teden statistično značilna za vse lipide/lipoproteine razen za TG in Apo A-1.
For patients who had their dose adjusted to 150 mg Q2W and who had two consecutive LDL-C values below 25 mg/dL (0.65 mmol/L), down-titration from 150 mg Q2W to 75 mg Q2W was performed.
Bolnikom, ki so jim odmerek povečali na 150 mg na 2 tedna in so imeli dve zaporedni vrednosti h-LDL pod 25 mg/dl (0,65 mmol/l), so odmerek zmanjšali s 150 mg na 2 tedna na 75 mg na 2 tedna.
Two multicenter, placebo-controlled, double-blind 18-month studies included 732 patients with heFH receiving a maximally tolerated dose of statin, with or without other lipid-modifying therapy.
Dve multicentrični, s placebom kontrolirani dvojno slepi 18-mesečni študiji sta zajeli 732 bolnikov s heFH, ki so jemali največji tolerirani odmerek statina, z drugimi zdravili za prilagoditev lipidov ali brez njih.
In the ODYSSEY OUTCOMES trial, 5.5% of patients treated with alirocumab 75 mg and/or 150 mg every 2 weeks (Q2W) had anti-drug antibodies (ADA) detected after initiating treatment compared with 1.6% of patients treated with placebo, most of these were transient responses.
V preskušanju ODYSSEY OUTCOMES so po uvedbi zdravljenja protitelesa proti zdravilu (ADA - antidrug antibodies) ugotovili pri 5,5 % bolnikov, ki so prejemali 75 mg in/ali 150 mg alirokumaba na 2 tedna, in pri 1,6 % bolnikov, ki so prejemali placebo; večinoma so bili ti odzivi prehodni.
After use put the syringe into a puncture-resistant container.
Po uporabi dajte brizgo v vsebnik za ostre odpadke.
At week 8, the mean reduction in LDL-C from baseline with all patients treated with alirocumab was 72.4%.
Po 8 tednih je bilo povprečno znižanje h-LDL v primerjavi z izhodiščem med bolniki, ki so dobivali alirokumab, 72,4 %.
Cardiovascular event defined as follows: CV death, any non-fatal CHD event, and non-fatal ischemic stroke f
e Srčno-žilni dogodek, opredeljen kot: srčno-žilna smrt, kateri koli koronarni dogodek brez smrtnega izida in ishemična možganska kap brez smrtnega izida.
• Throw away pen and cap into a puncture-resistant container immediately after use.
• Peresnik in pokrovček takoj po uporabi zavrzite v vsebnik za ostre odpadke.
Before you inject Read the detailed instructions for use leaflet before you inject Praluent.
Preden injicirate Pred injiciranjem zdravila Praluent preberite podrobnejša navodila za uporabo.
Sometimes serious allergic reactions such as hypersensitivity (difficulties breathing), nummular eczema (reddish skin spots sometimes with blisters), and hypersensitivity vasculitis (which is a specific form of a hypersensitivity reaction with symptoms such as diarrhoea, with a rash, or purple-coloured skin spots on the skin) have occurred in clinical studies.
V kliničnih študijah so se včasih pojavile resne alergijske reakcije, na primer preobčutljivost (težko dihanje), numularni ekcem (rdečkaste kožne pike, včasih z mehurji) in preobčutljivostni vaskulitis (posebna oblika preobčutljivostne reakcije, ki jo spremljajo simptomi, kot npr. driska z izpuščajem ali vijoličaste pike na koži).
This multicenter, double-blind, placebo-controlled, 18-month study included 2310 patients with primary hypercholesterolaemia at high or very high CV risk and on a maximally tolerated dose of statin, with or without other lipid-modifying therapy.
Ta multicentrična dvojno slepa s placebom kontrolirana 18-mesečna študija je zajela 2310 bolnikov s primarno hiperholesterolemijo in visokim ali zelo visokim KV tveganjem, ki so jemali največji tolerirani odmerek statina, z drugimi zdravili za prilagoditev lipidov ali brez njih.
In analyses of pooled phase 3 studies that allowed up-titration, among the subgroup of patients up-titrated, an increase from 75 mg Q2W to 150 mg Q2W alirocumab at week 12 resulted in an additional 14% mean reduction in LDL-C in patients on a background statin.
V kumulativnih analizah študij 3. faze, ki so dovoljevale povečanje, je bilo v podskupini bolnikov s povečanjem odmerka alirokumaba s 75 mg na 2 tedna na 150 mg na 2 tedna 12. teden doseženo dodatno 14 % povprečno znižanje h-LDL med bolniki, ki so prejemali osnovno zdravljenje s statinom.
After use put the pen into a puncture-resistant container.
Po uporabi dajte peresnik v vsebnik za ostre odpadke.
Talk to your doctor, pharmacist or nurse about all your medical conditions, including allergies, before using Praluent.
Preden uporabite zdravilo Praluent, se z zdravnikom, farmacevtom ali medicinsko sestro posvetujte o vseh svojih boleznih, tudi o alergijah.
If you miss a dose of Praluent, inject your missed dose as soon as you can. Then take your next dose at your regular scheduled time.
Če pozabite uporabiti odmerek zdravila Praluent, pozabljeni odmerek injicirajte čim prej.
Always use this medicine exactly as your doctor, pharmacist or nurse has told you.
Pri uporabi tega zdravila natančno upoštevajte navodila svojega zdravnika, farmacevta ali medicinske sestre.
Patients were randomized 1:1 to receive either alirocumab 75 mg once every two weeks (Q2W) or placebo Q2W.
Bolnike so v razmerju 1:1 randomizirali na prejemanje 75 mg alirokumaba na 2 tedna ali placeba na 2 tedna.
In the ODYSSEY OUTCOMES study, in which the starting alirocumab dose was 75 mg Q2W and the dose was increased to 150 mg Q2W if the patient's LDL-C was not <50 mg/dL (1.29 mmol/L), 54.8% of patients with baseline LDL-C <100 mg/dL and 24.2% of patients with baseline LDL-C ≥100 mg/dL treated with alirocumab had two consecutive values of LDL-C <25 mg/dL (<0.65 mmol/L).
V študiji ODYSSEY OUTCOMES, v kateri je bil začetni odmerek alirokumaba 75 mg na 2 tedna in so ga povečali na 150 mg na 2 tedna, če bolnikov h-LDL ni bil < 50 mg/dl (1,29 mmol/l), je imelo 54,8 % bolnikov z izhodiščnim h-LDL < 100 mg/dl (2,59 mmol/l) in 24,2 % bolnikov z izhodiščnim h-LDL ≥ 100 mg/dl (2,59 mmol/l), zdravljenih z alirokumabom, dve zaporedni vrednosti h-LDL < 25 mg/dl (< 0,65 mmol/l).
Skin and subcutaneous tissue disorders
Bolezni kože in podkožja srbenje urtikarija, numularni ekcem
In a pool of controlled studies using a 75 mg every 2 week (Q2W) starting dose and in which the dose was increased to 150 mg Q2W if the patient's LDL-C was not <70 mg/dL or < 100 mg/dL (1.81 mmol/L or 2.59 mmol/L), 29.3% of patients with baseline LDL-C <100 mg/dL and 5.0% of patients with baseline LDL-C ≥100 mg/dL treated with alirocumab had two consecutive values of LDL-C <25 mg/dL (<0.65 mmol/L).
V združenih (kumulativnih) kontroliranih študijah, kjer je bil začetni odmerek 75 mg na 2 tedna in v katerih so odmerek povečali na 150 mg na 2 tedna, če bolnikov h-LDL ni bil < 70 mg/dl ali < 100 mg/dl (1,81 mmol/l ali 2,59 mmol/l), je imelo 29,3 % bolnikov z izhodiščnim h-LDL < 100 mg/dl (2,59 mmol/l) in 5,0 % bolnikov z izhodiščnim h-LDL ≥ 100 mg/dl (2,59 mmol/l), zdravljenih z alirokumabom, dve zaporedni vrednosti h-LDL < 25 mg/dl (< 0,65 mmol/l).
All-cause mortality, non-fatal MI, non-fatal ischemic stroke CHD Death
Pomemben koronarni dogodekd kardiovaskularni dogodeke umrljivost zaradi vseh vzrokov, MI brez smrtnega izida, ishemična možganska kap brez smrtnega izida smrt zaradi koronarne bolezni srčno-žilna smrt
What Praluent contains
Kaj vsebuje zdravilo Praluent
At week 2, the mean reduction from baseline in LDL-C was 62.5% in the alirocumab-treated patients as compared to 8.8% in the placebo patients.
Po 2 tednih je bilo povprečno znižanje h-LDL v primerjavi z izhodiščem 62,5 % med bolniki, ki so dobivali alirokumab, in 8,8 % med bolniki, ki so dobivali placebo.